Close Menu

NEW YORK – GenMark Diagnostics reported after the close of the market Wednesday that its third quarter revenues rose 32 percent year over year, driven by growth in ePlex molecular diagnostic analyzer placements.

For the three months ended Sept. 30, the firm reported revenues of $20.9 million, up from $15.8 million a year ago, and edging the consensus Wall Street estimate of $20.4 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.